{"name":"Phio Pharmaceuticals","slug":"phio","ticker":"PHIO","exchange":"NASDAQ","domain":"phiopharma.com","description":"Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018.","hq":"Marlborough, MA","founded":0,"employees":"","ceo":"Gerrit Dispersyn","sector":"RNAi / Immuno-Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$18M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":4618000,"netIncome":-8698000,"cash":21031000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2020"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Phio Pharmaceuticals Announces FDA Clearance of Investigational New Drug (IND) Application for RP1","summary":"Phio Pharmaceuticals announced that the FDA has cleared the IND application for RP1, enabling the company to initiate a Phase 1 clinical trial.","drugName":"RP1","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results","summary":"Phio Pharmaceuticals reported its third quarter 2023 financial results, with a net loss of $4.4 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxQTm1acWJRYjEtZ2VBNEk2UlFoVzRnTjVKTHQ5QUlJTDBGM3JqY3JhMU9TeHlwa3diVDJsQkJtbVY5YkFtZGxGZktQOUgtUENmMGF0SHlERzVlVkc4Wm9vbFJJdnF1WnFDeng1ekJuamZoRHBWWFVKejc5RmVzTFc5d09TdU15dWNVZUVOVlBjNXo1TUlVMnExOV90YWtQNXdfMGQtQ0Ixa1BoN0RRVlFrTUhmTDVVY3J6YzFfTGI2elE0YmtqMGUyZlZfM3l4bFowbkc4dDllNFIyQVc1a3J6WnhqUTBLOXVIT1hRVW5CcWEwWjdSR3ZJc05jd1A?oc=5","date":"2026-03-16","type":"pipeline","source":"TMX Newsfile","summary":"Phio Pharmaceuticals Announces \"A Groundbreaking Approach to Treating Skin Cancer\" in a Fireside Chat with Force Family Office - TMX Newsfile","headline":"Phio Pharmaceuticals Announces \"A Groundbreaking Approach to Treating Skin Cancer\" in a Fireside Chat with Force Family ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOUUw0bUFMSFhJTzlQMTh0YmpXazNZVk9zR3QwX3pJMExnMFBna3dabDFnTXdsS3JreUQzU2xXVXRyc0JZRF9MRnBrcXBHOU41bjYtbUlpenI3UzNGcVk1SHhyTFcydnd0c0VjcHhuTjJ0ejRrZmYwWEZ1MDZvY2RCeHFTN2ZEMjB4bWl0bGtxUjFfb1JBUGV3NExvOGUxNVh4MWtJQjA1Z3ExcTR0YnhUTEdGQjh6RVNxS1dobUVKYzM?oc=5","date":"2026-03-16","type":"trial","source":"Stock Titan","summary":"Phio cancer study sees ~65% response; CEO in March 18 virtual chat - Stock Titan","headline":"Phio cancer study sees ~65% response; CEO in March 18 virtual chat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPblRvcGpCRC1RcmRTenRTMy11ZFlWSDczeFN5UENKT3Nzb3diVW9mMkd2dURweVhNV2NNZEt0STJ2ZXhEQVNZMFBXYXhUSlFpTFg4bmVDdWMxTm9lUk5ua082bDNUSGlXRWE2cmwxS0l0NWNxWE45TERVZHZseGp1elI4aFIycm0tTWl1NzR4WFBkTVFCVEx6QjJZa3B2MzdVNXYybEJuZVFqQldfc2d4UEdKZ05Ld01ITnN6bnFKaw?oc=5","date":"2026-03-10","type":"trial","source":"Stock Titan","summary":"Cancer gene-silencing trial shows 65% response in Phio study - Stock Titan","headline":"Cancer gene-silencing trial shows 65% response in Phio study","sentiment":"neutral"},{"date":"2026-03-05","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxPVnhTVVNNS3JKb0tjbWQxMkNsOU5SVGFUOXNxMkp4X1hwdEZuUlY3bG4xTXpHVEpKOEFwaW15Rl8xS3cxMUJBT3ZMQU1NYlJ0RFhGRnJEdkpoam91aGxETUlBbGVtLWk5THl5M3NwS2ZQajd4NGRnWWlfb2w5SVAwMm81ajhtNmZ0Y05zT1F0b0VqRmFwNGZEV0xDS2lpOTBTbG9PZkk4YlVhNmpEYnN0dm13dktvNnRnVkJHNjVtXzRjSWFKZERZOWV6X0ZhWHFHWkRUeDdXTmhBd1pZVjFZ?oc=5","date":"2026-02-23","type":"pipeline","source":"EQS News","summary":"Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company | Corporate - EQS News","headline":"Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company | Corporate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNVmtRbVpWeXJBbV9nMEhTTmNudTJ1Rl9WNURQQS0xLUF5NTN2VWE4MENVbDVDekRFSHlQOWU0c2JUdW9VTVZ0TkMxVkpfTUFWZERBZFJCVEltbTgzVDVTT3g3S2tKVlAtRk1aSlJkMkpVSnRVcDdaV2JBdm5PeEVLQ1hoS0IxZjJjMlJaWHZSYzlCeWs?oc=5","date":"2026-02-19","type":"pipeline","source":"Yahoo Finance","summary":"Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894 - Yahoo Finance","headline":"Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894","sentiment":"neutral"},{"date":"2026-02-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQZ1VPcW9MSTNzZ0ZDNS1mb2xTd3FSOHRfYVlwLTNxVlFFNUpCSzQ3QXlocC1FMjB6YW8wc2dCU09BbGYwRFZoTEhqSkwweXVzTnlsNW9Cc1Btbjl4ZzJsU0JpTng0a2luWVFyTkFzcHJFR3p1QkcwVnozWFNETTE1ZVJGVXBwRHAwLXNhak04Z2NYZjdYUjNyTVBBb3Q4cVFiTkZ0X2Z0ODJQSGVydC1IUDhxX0Z3a3NpTVRSRGIxdm9Fai1hNGNqZA?oc=5","date":"2026-02-12","type":"pipeline","source":"Benzinga","summary":"What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday? - Benzinga","headline":"What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNVjVMb1NPRXhVUjFDTVF2OEFoblVuc2I5N1BWTVdtdExGbDdvRjBUbmlLRW1aTm5qSjZhQUp5R1NjOEMwTTdZSUN6ckl6NmtDQ0xVRDdkeXpsWnB4eUJJdkI4dUxRdDM3Rk9vdGJqRGYzODdtd1VDRlVkUDM1UUVRalhBTVhfLWtyNkpuYUFCWGg2Zi12YTFrdzlzX0tUZGNjSzFSeVpVS3NEOTJadlRrNlFJd1dFMjBLZE4tcA?oc=5","date":"2026-02-10","type":"trial","source":"TipRanks","summary":"Phio Pharmaceuticals Reports Positive PH-762 Phase 1b Safety Results - TipRanks","headline":"Phio Pharmaceuticals Reports Positive PH-762 Phase 1b Safety Results","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxOM0Rfd3Zaa19kX3g3N0dqMGNVck5BWk50aDliMFNMd0xqUnhXcEpXdTgtR3RkU19yYTJ1QW5IOVdRYmZ5RFRzN2dTV3MwLWVTUmI4T1k4Vmt5bmFfellOUzZjd2g4TVhjWFVDTDhBYjdadjZlM1h0Wm42WW5kM0lKb0Rxc2I5YlZWbjdSSDliYVhGUk5LQ21CSjFCNllxWC1ROEJ6VG9PZm51TkZlZWViTk9YNnhrei1RTndYUTBrRW9oT1MyY1lRSDdOMHUzdFo3cEp2TUhLOU1TM0l4Nzdra2thOHZVUnBKY2h3NGZWZlRLcE5VdEp2S0JjZFgzQ3NsZ25LbWtZTQ?oc=5","date":"2026-02-10","type":"trial","source":"Benzinga","summary":"Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin C - Benzinga","headline":"Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin C","sentiment":"neutral"},{"date":"2026-02-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-01-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxOaWRTd25RTVowZjhwcUdkWU9YQWp6UUptdGRQME9yd08yMS1yUUN1SmN4ckMza3NLRmpEdVlTZFBUM2tXWFZXMzZZVzAzWkFsSEFMZDg1SXlkdVR2VXRYTFg2aThhNzMyaTZ0RFpzSjBfamdSRTJxTDFZVFR0QVRXa3liSWZ6Y2tRU28wbUxkMUVYMXd5MC1lblNBVHQ4cVBZX2djajlUTlo4ZTh4QkZUMlRGUmtyZjBpVDlPZ2kyS3lZVXdaR3QwbkVucTh5YnVqSVlkVFBUODg?oc=5","date":"2025-12-23","type":"pipeline","source":"TMX Newsfile","summary":"Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762 - TMX Newsfile","headline":"Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["BioNTech","Moderna Therapeutics","Alnylam Pharmaceuticals"],"therapeuticFocus":["Immunotherapy","RNA Therapeutics"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2020-12-31","revenueHistory":[{"value":0,"period":"2020-12-31"},{"value":21000,"period":"2019-12-31"},{"value":138000,"period":"2018-12-31"},{"value":15000,"period":"2017-12-31"},{"value":19000,"period":"2016-12-31"},{"value":34000,"period":"2015-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":4618000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-8698000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":21031000,"cashHistory":[],"totalAssets":21487000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}